NG-641 is under clinical development by Akamis Bio and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NG-641’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NG-641 is under development for the treatment of metastatic epithelial cancer and head and neck squamous cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck (SCCHN), microsatellite instability (MSI)-high/deficient mismatch repair (dMMR) cancer, non-small cell lung cancer (NSCLC), uterine cancer, endometrial cancer, cervical cancer, pancreatic cancer, colorectal cancer, liver cancer, esophageal cancer, gastric cancer, triple-negative breast cancer (TNBC), cutaneous squamous cell carcinoma and hepatocellular carcinoma. The drug candidate is administered through intravenous and intratumoral routes. The therapeutic candidate is a next-generation enadenotucirev (EnAd). NG-aFAP consists of anti-fibroblast activation protein and stromal cell targeting, bi-specific antibody-producing virus. It is developed based on tumor-specific immuno-gene therapy (T-SIGn) delivery technology.
Akamis Bio overview
Akamis Bio, formerly PsiOxus Therapeutics Ltd, develops and discovers novel therapies for the treatment of cancer and other related diseases. The company utilizes T-SIGn, a tumor specific immuno gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio’s product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. The company is also investigating NG-347, NG-348, and NG-796A drug programs for application in various cancer treatments. It has an operational presence in the US and the UK. Akamis Bio is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of NG-641’s drug-specific PTSR and LoA scores, buy the report here.